

Cover Story
Free
By Matthew Bin Han Ong
The Blue Ribbon Panel—a group of experts selected to identify scientific opportunities for the National Cancer Moonshot Initiative—has submitted 10 recommendations to the National Cancer Advisory Board.
By Laura Brawley
In Brief


Drugs & Targets


Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ













